Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Roche receives FDA approval for companion diagnostic tests to identify patients with HER2 ...

26 August 2026 · By · Wire by Fusion42

Published

26 August 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at prnewswire.com →

◆ Verified

Fusion42 · 26 August 2026 · Fusion42 review

Roche has received FDA approval for companion diagnostic tests designed to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma who are eligible for treatment with ZIIHERA.

This Wire brief sits within Fusion42's coverage of Medtech, and 2 sources have reported it between 26 Aug 2026 and 27 Aug 2026.

◆ ◆ The Wire takeaway

You now have a clearer route to market in US cancer diagnostics focused on HER2-positive metastatic gastroesophageal adenocarcinoma. Prioritise collaborations with Roche or access to their diagnostic tests to expand patient targeting in this niche.

◆ Coverage

2 sources · first reported 26 Aug 2026 · latest 27 Aug 2026

◆ Related on Wire

◆ Topics

MedtechFDA-approvaldiagnosticscancerHER2Roche